Cargando…
Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial
BACKGROUND: Given the recent approval of oral berotralstat in several countries for hereditary angioedema (HAE) prophylaxis, transition from long-term androgens to berotralstat may occur in clinical practice. The open-label, Phase II APeX-S trial provided an opportunity to assess the safety and effe...
Autores principales: | Peter, Jonny G., Desai, Bhavisha, Tomita, Dianne, Collis, Phil, Stobiecki, Marcin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665923/ https://www.ncbi.nlm.nih.gov/pubmed/38020288 http://dx.doi.org/10.1016/j.waojou.2023.100841 |
Ejemplares similares
-
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021) -
Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability
por: Diaz-Menindez, Maximiliano, et al.
Publicado: (2023) -
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
por: Ohsawa, Isao, et al.
Publicado: (2020) -
Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022) -
Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns
por: Nieto, Sandra, et al.
Publicado: (2023)